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Presence of AmpC Beta-Lactamases, CSA-1, CSA-2, CMA-1,
and CMA-2 Conferring an Unusual Resistance Phenotype
in Cronobacter sakazakii and Cronobacter malonaticus
Andrea Mu¨ller, Herbert Ha¨chler, Roger Stephan, and Angelika Lehner
Here we describe the presence of two very similar but unusual variants of AmpC cephalosporinase in each
Cronobacter sakazakii and C. malonaticus isolates conferring resistance exclusively to first generation ceph-
alosporins. During a survey on the antibiotic resistance patterns of C. sakazakii and C. malonaticus strains
isolated from a milk powder production facility, originally two different phenotypes regarding the suscepti-
bility/resistance for the two beta-lactam antibiotics ampicillin (amp) and cephalothin (ceph) were observed: (i)
isolates being susceptible for both antibiotics (ampS/cephS), and (ii) strains exhibiting susceptibility to ampi-
cillin but resistance to cephalothin (ampS/cephR). The latter phenotype (ampS/cephR) was observed in the
majority of the environmental strains from the facility. Analysis of whole genome sequences of C. sakazakii
revealed a gene putatively coding for an AmpC beta-lactamase. Consequently, the ampC genes from both
species and both phenotypes were subjected to a cloning approach. Surprisingly, when expressed in Escherichia
coli, all transformants exhibited the ampS/cephR phenotype regardless of (i) the phenotypic backgrounds or (ii)
the AmpC amino acid sequences of the original strains from which the clones were derived. The novel AmpC
beta-lactamases were designated CSA-1 and CSA-2 (from C. sakazakii) and CMA-1 and CMA-2 (from C.
malonaticus). The observed variations in the minimum inhibitory concentration (MIC) levels for cephalothin
(wt compared to transformants) suggest that this feature is a target of a yet unknown regulatory mechanism
present in the natural Cronobacter background but absent in the neutral E. coli host.
Introduction
According to the List of Prokaryotic Names withStanding in Nomenclature (www.bacterio.net/allname-
sac.html), the genus Cronobacter was proposed in 2008 and
currently consists of seven species, which encompass or-
ganisms previously identified as Enterobacter sakazakii.8,9
Members of this genus are considered opportunistic patho-
gens, and are associated with outbreaks and sporadic in-
fections, particularly in low birth weight and premature
infants.1,12,13 Symptoms include bacteremia, necrotizing en-
terocoliti,s and meningitis, with fatality rates between 10%
and 42%.6 The prognosis for survivors is generally poor, and
neurological delay and poor lifelong outcomes may occur in
more than 74% of cases.19 Antibiotic susceptibility testing,
when available, showed that Cronobacter isolates were
usually sensitive to ampicillin, the aminoglycosides, chlor-
amphenicol, and third generation cephalosporins.13 How-
ever, in a study by Lai,10 cases of nosocomial Cronobacter
infections were examined, thereby revealing that all of the
isolates were uniformly resistant to ampicillin, cephazolin,
and extended spectrum penicillins, and were not uniformly
susceptible to the third generation cephalosporins.
Antimicrobial susceptibility testing on environmental
Cronobacter spp. isolates, as performed in more recent
studies, indicated susceptibility to ampicillin (and all
cephalosporins), thus leading to speculations that Crono-
bacter wild type strains may lack a beta-lactamase.4,7
Genera such as Enterobacter, Citrobacter, Serratia, Pro-
teus, Providencia, and Morganella usually express a chro-
mosomal, inducible group I AmpC type beta-lactamase that
confers strong resistance to penicillins (including ampicillin
and inhibitor combinations) and first to third generation
cephalosporins.11
In this study, we analyzed C. sakazakii and C. malonaticus
strains originating from a milk powder production facility and
respective species type strains for their antimicrobial resistance
against the two major beta-lactam antibiotics—ampicillin and
cephalothin—in order to answer the question of the presence/
expression of a beta-lactamase in Cronobacter.
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Material and Methods
Strains and antibiotic susceptibility testing
In a study by Mu¨ller et al.,14 139 C. sakazakii and
C. malonaticus isolates from a milk powder production fa-
cility were collected and characterized using several typing
methods. These isolates were examined in this study for
their resistance against major antibiotics using the disk
diffusion assay,3 as well as by determining the minimum
inhibitory concentration (MIC) values by means of the
E-Test (Biomerieux) for four selected strains, two from the
above mentioned study—C. sakazakii Su 92 and C. mal-
onaticus Su 126—as well as two type strains—C. sakazakii
ATCC 29544T and C. malonaticus type strain LMG 23826T.
Escherichia coli DH5 alpha as well as E. coli DH5 alpha
harboring the pCCR9 cloning vector were included in the
study. Cronobacter strains and E. coli DH5 alpha were cul-
tivated in LB, transformants and E. coli DH5 alpha harboring
pCCR918 vector were grown in LB supplemented with tet-
racycline (50mg/L) at 37C overnight. Strains used in the
study and respective susceptibility data are given in Table 1.
Identification of a putative beta-lactamase gene
in C. sakazakii ES15 and primer design
A database search was performed on the whole genome
sequence available for C. sakazakii ES15 (GenBank:
CP003312.1) and a coding sequence (CDS) annotated as
putative beta-lactamase (ampC, GenBank: AFJ99606.1,
genome position: 2.159.483–2.160.610) was identified.
Analysis of the regions up- and downstream of this CDS
revealed a putative promoter element. Based on these data,
PCR primers (CampCf: 5¢-TGA ACC AGA ACG GAT
TAG CCC-3¢, genome position: 2.160.772–2.161.793; and
CampCr: 5¢-CAG CGA TGC CGA CTT CAA CGC-3¢,
genome position: 2.159.338–2.159.359) were designed and
employed in order to amplify this CDS in the four selected
Cronobacter strains using the following conditions: 20 ng
template DNA, 0.4 mM primers, 1 ·AccuPrime (Invitrogen)
buffer 2 (60mM Tris-SO4 [pH 8.9], 18mM [NH4]2SO),
2mM MgSO4, 2mM dGTP, 0.2mM dATP, 0.2mM
dTTP, 0.2mM dCTP, thermostable AccuPrimeTM protein,
1% glycerol, 2U AccuPrime Taq DNA Polymerase High
Fidelity (Invitrogen). The following PCR conditions were
employed: 94C for 30 s followed by 35 cycles of 94C for
30 s, 54C for 30 s, and 68C for 120 s. DNA was extracted
from LB cultures grown overnight using the Qiagen Blood
and Tissue Kit (Qiagen). The 1309 bp amplicons were
successfully amplified and sequenced using the above
mentioned primers.
Sequencing and sequence analysis
Sequencing of the ampC amplicons and the respective
transformant inserts was outsourced (Microsynth). Sequence
analysis was performed using the CLC Main Workbench 5
software.
Cloning of ampC CDS ( + promoter element)
For cloning purposes, the above mentioned primers were
extended by a HindIII (forward primer) and a BamHI (re-
verse primer) restriction enzyme recognition sequence. The
amplicons were double digested, purified using the Qiagen
PCR purification Kit. Vector pCCR9 DNA was obtained
using the Qiagen Plasmid Midi Kit double digested with the
above mentioned enzymes, (0.7% agarose) gel purified, and
DNA was released employing the Qiagen Gel purification
Kit. Vector-insert ligation was performed using the T4
ligase (New England Biolabs). Constructs were transformed
in E. coli DH5 alpha cells by electroporation.
Accession numbers
The ampC gene sequences of the isolates included in this
study were deposited in Genbank under the following num-
bers: C. sakazakii ATCC 29544T (encoding AmpC, which
was designated CSA-1)=KF623543; C. sakazakii Su 92
(encoding AmpC, which was designated CSA-2)=KF640250;
C. malonaticus LMG 23826T (encoding AmpC, which was
designated CMA-1)=KF640251; C. malonaticus Su126 (en-
coding AmpC, which was designated CMA-2)=KC665723.
Table 1. Minimal Inhibitory Concentrations
of Two Critical Antibiotics Observed
in the Four Selected Cronobacter Strains,
Their Respective Escherichia coli DH5 Alpha
Transformants, the Cloning Host E. coli DH5
Alpha, and the Cloning Host Containing
the Empty Cloning Vector pCCR9
Strains Ampicillina Cephalothina
C. sakazakii ATCC
29544T wt
1 32
E. coli DH5 alpha + pCCR9::
ampCATCC 29544T
4 > 256
C. sakazakii Su 92wt 1 8
E. coli DH5 alpha +
pCCR9::ampCSu92
8 > 256
C. malonaticus Su 126wt 1.5 32
E. coli DH5 alpha +
pCCR9::ampCSu126
3 48
C. malonaticus
LMG 23826T wt
0.5 3
E. coli DH5 alpha +
pCCR9::ampCLMG 23826T
4 128
E. coli DH5alpha 0.75 1.5
E. coli DH5 alpha + pCCR9 1.5 1.5
aGiven in mg/L, scores: £ 8: susceptible, ‡ 32 resistant (CLSI,
2013).
FIG. 1. Analysis of the four Cronobacter ampC/AmpC sequences including those of the strains Serratia marcescens SST-
1 (AB008455.1, BAA23131) and Pantoea sp. At-9b (YP_004115822.1). (A) Nucleic acid alignment of the 5¢ untranslated
(promoter) regions of the ATG start codon is written in bold. (B) Amino acid alignment of the translated CDS; the catalytic
site including the active serin at amino acid position 80 as well as a second potential site at amino acid position 240 most
likely representing two components of the catalytic triad are boxed. (C) Nucleic acid alignment of the 3¢ untranslated region.
TAA stop codon is written in bold.
‰
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Results
Screening of 139 Cronobacter spp. isolates originating
from a milk powder production facility as well as the two
type strains for the species C. sakazakii and C. malonaticus
for their antibiotic resistance suggested the presence of
two different susceptibility patterns regarding the two beta-
lactam antibiotics ampicillin and cephalothin in the two
species: (i) ampS/cephS and (ii) ampS/cephR. The majority
(87%) of the strains exhibited susceptibility to ampicillin but
intermediate or full resistance to cephalothin. In the re-
maining strains, the ampS/cephS phenotype was observed. In
an effort to elucitate the molecular bases of this feature, four
strains were selected for further experiments: C. sakazakii
type strain 29544T (ampS/cephR), C. sakazakii isolate Su 92
(ampS/cephS), C. malonaticus LMG 23826T (ampS/cephS),
and C. malonaticus Su 126 (ampS/cephR).
A database search was performed on the whole genome
sequence available for C. sakazakii ES15 (GenBank:
CP003312.1), and a coding sequence (CDS) annotated as
putative beta-lactamase (ampC, GenBank: AFJ99606.1,
genome position: 2.159.483–2.160.610) was identified.
Based on these data, primers were designed spanning the
CDS, including a putative promoter element. The putative
ampC genes were successfully amplified in all four target
strains, and amplicons were subjected to sequencing.
Deduced protein sequences revealed that the four Crono-
bacter AmpC showed the highest—although still relatively
low—protein homology to AmpC in Serratia marcescens
SST-1 (65–66% identity, BAA23131) and Pantoea sp. At-9b
(68–69% identity, YP_004115822.1). In Fig. 1, the nucleic
acid alignment of the 5¢ untranslated (promoter) region (1A),
the amino acid alignment of the translated CDS (1B), as well
as the nucleic acid alignment of the 3¢ untranslated region of
the four Cronobacter AmpC sequences, including the Ser-
ratia marcescens SST-1 (AB008455.1, BAA23131) and
Pantoea sp. At-9b (YP_004115822.1) (1C), is depicted.
The ampC CDS of the four Cronobacter strains originally
exhibiting divergent cephalothin resistance patterns were
cloned and expressed in E. coli DH5 alpha. Determination
of the MICs by means of the E-tests revealed (although
with minor variations) identical susceptibility patterns for
all transformants, namely susceptibility to ampicillin and
resistance to cephalothin, according to CLSI interpreting
criteria (Table 1).
AmpC beta-lactamases are cephalosporinases from the
functional group 1 and molecular class C in the Bush–
Jacoby–Medeiros classification scheme of beta-lactamases.
FIG. 2. Results of double disk inducer (cefoxitin) experiments on C. sakazakii ATCC 29544T, C. malonaticus Su 126, and
their respective Escherichia coli transformants. Inducer disk (Fox30) placed in the middle of each plate, and three synergy
indicator disks (CF30) placed in the vicinity of Fox30 separated by distances of 10, 15, and 25mm, respectively.
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They are not inhibited by beta-lactamase inhibitors such as
clavulanic acid. Additionally, certain beta-lactams such as
cefoxitin, clavulanic acid, and carbapenems are strong
AmpC beta-lactamase inducers. In order to test a potential
induction effect possibly affecting the phenotype for ceph-
alothin, double disk experiments were carried out using ei-
ther amoxicillin/clavulanic acid or cefoxitin as inducers. For
this purpose, the potential inducer disk was placed adjacent
to three cephalothin disks, separated by distances of 10, 15,
and 25mm respectively, on Mueller Hinton agar. Figure 2
exemplifies the results of these experiments for the cefox-
itin/cephalothin combination. No antagonistic effect was
observed, as would have been expected in the case of in-
duction. Results from analogous experiments using amoxi-
cillin/clavulanic acid as an inducer were comparable (data
not shown). In conclusion, the results showed that (i) Cro-
nobacter wt and respective E. coli ampC transformants were
fully susceptible to cefoxitin, and (ii) no induction effect
was observed.
In many organisms, including Enterobacter spp., the ex-
pression/induction of the ampC appears to involve several
gene products associated with this regulation. These gene
products include AmpR, AmpD, and AmpG. Performing a
GenBank homology search for these regulatory elements
revealed that both C. sakazakii and C. malonaticus harbor
homologues for AmpG and AmpD. However, no homologue
could be identified for the key AmpC regulator AmpR in
either of the two species (data not shown). This finding (i.e.,
absence of ampR) is further evidence in support of our ex-
perimental observation of the Cronobacter beta-lactamase
being noninducible.22
Discussion
The presence/expression of a beta-lactamase in Crono-
bacter has been discussed controversially in the literature.
Several studies have suggested that Cronobacter is susceptible
to beta-lactam antibiotics.13,15,21 However, the presence of
beta-lactamases in Cronobacter was confirmed in a study by
Pitout et al.17 who showed that Cronobacter strains sensitive
to all cephalosporins, including cefoxitin, produced Bush
group 1 beta-lactamases with isoelectric points of 7.4–8.0 at
low levels. Enterobacteriaceae species, which naturally ex-
press their beta-lactamases at negligible or low levels, are not
uncommon, and include several species (e.g., Shigella spp.,16
Proteus mirabilis,11 and Edwardsiella tarda20).
We used a cloning approach in order to answer the
question of the presence and the expression of a (AmpC)
type beta-lactamase in Cronobacter isolates. This was a
somewhat surprising result, as the strains were originally
selected due to the observed differences in their resistance to
cephalothin in their wild type background. The higher MIC
values for ampicillin in the transformants may be explained
as ‘‘gene dosage effect,’’ that is, copy (and thus the gene
copy) number of the (low copy) pCCR918 vector versus
single chromosomal copy. By this approach, we could show
that C. sakazakii and C. malonaticus possess group C beta-
lactamases2 with a highly specialized phenotype. The se-
quences of the novel AmpC beta-lactamases were deposited
in GenBank and designated as follows: CSA-1 (C. sakazakii
ATCC 29544T); CSA-2 (C. sakazakii Su 92); CMA-1
(C. malonaticus LMG 23826T); and CMA-2 (C. malonaticus
Su 126). The divergences in cephalothin MIC values, as
observed before and after cloning of the ampC genes of
Cronobacter strains exhibiting the ampS/cephS phenotype,
may be explained by the presence of yet unknown influ-
encing factors present in the natural Cronobacter back-
ground, but absent in E. coli.
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